Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study is a research paper published in Annals of Oncology (2022). On theSindex it has a DataRank of 7.1. It has been cited 352 times, with 200 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.880
From this paper's citation signal
Citation Network Contribution
6.3
From 200 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 200 citers.
NCI NIH HHS
Grant: R01 CA242845
Intramural NIH HHS
Grant: ZIA BC010301
NCI NIH HHS
Grant: P30 CA016672
NCI NIH HHS
Grant: U01 CA180964
NCATS NIH HHS
Grant: UL1 TR000371
National Institutes of Health
Grant: 5U01CA180964-02
Informatics to enable routine personalized cancer therapy
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
National Institutes of Health
Grant: 5R01CA242845-04
Blocking tumor progression in therapy-responsive RET aberration-associated cancer
National Institutes of Health
Grant: 4UL1TR000371-10
Center for Clinical and Translational Sciences (CCTS)
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study
Additional file 1 of First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study
Additional file 2 of First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study
Additional file 2 of First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study
Additional file 2 of Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics
Additional file 2 of Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics
Additional file 1 of Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics
Additional file 1 of Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics